Less-invasive BPH (benign prostatic hyperplasia) treatment cleared for US sale:
This article was originally published in Clinica
The US FDA has cleared for sale Gyrus' Endourology system, which uses PlasmaKinetic radiofrequency technology to remove part of the prostate in patients with benign prostatic hyperplasia. The system is the third using PlasmaKinetic technology to be cleared by the FDA - the VAPR arthroscopy device and the VersaPoint hysteroscopic system are already sold in that market. The Cardiff, UK-based company now plans to begin discussions with potential US distributors for the Endourology system.